Dr. Borghaei on Second-Line Therapy in SCLC
November 10th 2018Hossein Borghaei, DO, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the evolving second line of treatment in small cell lung cancer.
Expert Discusses Next Steps With Immunotherapy in Lung Cancer
Hossein Borghaei, DO, discuss what lies ahead for immunotherapy in lung cancer, and what changes may be on the horizon for such agents as pembrolizumab (Keytruda), nivolumab (Opdivo), and ipilimumab (Yervoy) in the frontline setting.
Dr. West on Considering Factors for EGFR TKIs in NSCLC
November 15th 2016H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses factors he takes into consideration for EGFR tyrosine kinase inhibitors in patients who have EGFR-positive non–small cell lung cancer (NSCLC).
Emerging Data Could Rearrange Frontline EGFR TKIs in NSCLC
November 13th 2016Individualizing frontline therapy for patients with non–small cell lung cancer based on preferences and clinical experience, as well as efficacy and safety data from pivotal trials, is an appropriate method for selecting EGFR-targeted agents.
Therapeutic Options Expanding for ALK-Rearranged NSCLC
November 13th 2016The treatment landscape for patients with ALK-rearranged non–small cell lung cancer is changing rapidly, gearing up the potential for more therapeutic options to address the heterogeneity of the mechanism of resistance in this population.
Dr. Perez-Soler on Impact of Osimertinib on Field of NSCLC
November 13th 2016Roman Perez-Soler, MD, chairman of the Department of Oncology and chief of the Division of Medical Oncology at Montefiore Medical Center, Albert Einstein College of Medicine of Yeshiva University, discusses the impact of osimertinib (Tagrisso) on patients with T790M-positive non–small cell lung cancer (NSCLC).
Dr. Chandra Belani on Selecting Anti-PD-L1 Agents in Lung Cancer
Chandra P. Belani, MD, deputy director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses results seen with anti–PD-1/PD-L1 treatments in lung cancer.